Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$236.34 USD
-5.84 (-2.41%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $236.50 +0.16 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.34 USD
-5.84 (-2.41%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $236.50 +0.16 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Here's Why You Should Hold Becton, Dickinson Stock for Now
by Zacks Equity Research
Becton, Dickinson (BDX) announces the FDA premarket approval for Venovo venous stent device.
BD Remains Confident About LUTONIX DCB Despite FDA Letter
by Zacks Equity Research
Per the recent press release issued by BD (BDX), it seems that the company still has immense confidence on the LUTONIX DCB.
Stock Market News For Mar 15, 2019
by Zacks Equity Research
Wall Street closed mixed on Thursday as investors??? remained anxious about the delay in sealing a U.S. ??? China trade deal.
BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost
by Zacks Equity Research
Becton, Dickinson (BDX) receives a number of regulatory approvals of late.
Becton Dickinson (BDX) Up 2.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Becton, Dickinson Stock for Now
by Zacks Equity Research
Becton, Dickinson's (BDX) MAX enteric viral panel receives FDA clearance.
BD Gains From Solid Global Base, Headwinds Anticipated
by Zacks Equity Research
Becton, Dickinson's (BDX) solid geographical expansion encourages; raw material pricing pressure raises concern.
The Zacks Analyst Blog Highlights: Procter & Gamble, Becton, Dickinson, Dominion, Chubb and Estee Lauder
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Becton, Dickinson, Dominion, Chubb and Estee Lauder
Top Analyst Reports for Procter & Gamble, Becton, Dickinson & Dominion Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Becton, Dickinson (BDX) and Dominion Energy (D).
Market Awaits A Flood of Q4 2018 Earnings Data
by Zacks Equity Research
Market Awaits A Flood of Q4 2018 Earnings Data.
Heavy Q4 Reporting Ahead of State of the Union Address
by Mark Vickery
Investors will be playing close attention to the president's comments on taxes, spending and congressional harmony (or lack thereof).
Becton, Dickinson (BDX) Q1 Earnings In Line With Estimates
by Zacks Equity Research
Strong segmental performance favors Becton, Dickinson's (BDX) fiscal Q1 results.
Becton Dickinson (BDX) Meets Q1 Earnings Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.00% and -0.05%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q2; medical-gloves sub-segment likely to be soft.
AmerisourceBergen (ABC) Jumps: Stock Rises 6.2%
by Zacks Equity Research
AmerisourceBergen (ABC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?
by Zacks Equity Research
Myriad (MYGN) likely to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
Why the Earnings Surprise Streak Could Continue for Becton Dickinson (BDX)
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Varian Strong on Global Expansion and Proton Therapy Arm
by Zacks Equity Research
Varian's (VAR) strong presence in China instills optimism in the stock.
Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) solid fiscal first-quarter preliminary results boost optimism in the stock.
Accuray's (ARAY) Q2 Loss Narrows, Radixact Demand Shoots Up
by Zacks Equity Research
Demand for flagship Radixact & CyberKnife platforms aids Accuray's (ARAY) fiscal Q2 results.
CONMED (CNMD) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
CONMED's (CNMD) Q4 results get a boost from solid segmental performances.
Here's Why Investors Should Bet on Abiomed (ABMD) Stock Now
by Zacks Equity Research
Strong contribution from Impella product line is likely to provide Abiomed (ABMD) a competitive edge in the MedTech space.
Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Becton, Dickinson and Company, ArcBest, Tetra Tech and Nexstar Media
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Becton, Dickinson and Company, ArcBest, Tetra Tech and Nexstar Media
5 Cheap Dividend Stocks That Offer Growth
by Sweta Killa
Amid heightened volatility and uncertainty, investors are looking for both income and growth in their portfolio. As a result, picking dividend growth stocks appear as a winning strategy.